Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer

Mary Cianfrocca; William J. Gradishar

doi:10.6004/jnccn.2007.0069

Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer

Mary Cianfrocca, William J. Gradishar^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

Original language	English (US)
Pages (from-to)	673-675
Number of pages	3
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	5
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2007.0069
State	Published - Sep 2007

Keywords

Chemotherapy
Combination therapy
Metastatic breast cancer
Polychemotherapy
Single agent

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2007.0069

Fingerprint Dive into the research topics of 'Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

@article{bb170f3ed7134bf2ae4a418c15c221e3,

title = "Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer",

abstract = "The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.",

keywords = "Chemotherapy, Combination therapy, Metastatic breast cancer, Polychemotherapy, Single agent",

author = "Mary Cianfrocca and Gradishar, {William J.}",

year = "2007",

month = sep,

doi = "10.6004/jnccn.2007.0069",

language = "English (US)",

volume = "5",

pages = "673--675",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "8",

}

TY - JOUR

T1 - Counterpoint

T2 - The argument for combination chemotherapy in the treatment of metastatic breast cancer

AU - Cianfrocca, Mary

AU - Gradishar, William J.

PY - 2007/9

Y1 - 2007/9

N2 - The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

AB - The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

KW - Chemotherapy

KW - Combination therapy

KW - Metastatic breast cancer

KW - Polychemotherapy

KW - Single agent

UR - http://www.scopus.com/inward/record.url?scp=34848814488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848814488&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2007.0069

DO - 10.6004/jnccn.2007.0069

M3 - Article

C2 - 17927925

AN - SCOPUS:34848814488

VL - 5

SP - 673

EP - 675

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 8

ER -

Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this